SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Total Receivables
SCI Pharmtech Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Total Receivables
NT$289.5m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
2%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Total Receivables
NT$1.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Total Receivables
NT$1.3B
|
CAGR 3-Years
16%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Total Receivables
NT$654.2m
|
CAGR 3-Years
19%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Total Receivables
NT$7.7B
|
CAGR 3-Years
31%
|
CAGR 5-Years
26%
|
CAGR 10-Years
12%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Total Receivables
NT$1.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Total Receivables?
Total Receivables
289.5m
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Total Receivables amounts to 289.5m TWD.
What is SCI Pharmtech Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
2%
Over the last year, the Total Receivables growth was -6%. The average annual Total Receivables growth rates for SCI Pharmtech Inc have been -6% over the past three years , -4% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet